Cargando…
Inhibition of Th17 cells by donepezil ameliorates experimental lung fibrosis and pulmonary hypertension
Rationale: Pulmonary hypertension (PH) secondary to lung fibrosis belongs to WHO Group III, one of the most common subgroups of PH; however, it lacks effective treatment options. Cholinesterase inhibitor donepezil (DON) has been shown to effectively improve Group I PH. However, its effects on Group...
Autores principales: | Guo, Yuan, He, Ziyu, Chen, Zhu, Chen, Fengling, Wang, Chengming, Zhou, Wanlu, Liu, Jie, Liu, Hao, Shi, Ruizheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091879/ https://www.ncbi.nlm.nih.gov/pubmed/37064881 http://dx.doi.org/10.7150/thno.82069 |
Ejemplares similares
-
Donepezil Ameliorates Pulmonary Arterial Hypertension by Inhibiting M2-Macrophage Activation
por: Qiu, Haihua, et al.
Publicado: (2021) -
Ameliorative Potential of Donepezil with or without Prednisolone in Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of the Anti-Inflammatory, Antioxidant, and the Antifibrotic Pathways
por: Mina, Shery, et al.
Publicado: (2023) -
Aging weakens Th17 cell pathogenicity and ameliorates experimental autoimmune uveitis in mice
por: Li, He, et al.
Publicado: (2021) -
MicroRNA‐483 amelioration of experimental pulmonary hypertension
por: Zhang, Jin, et al.
Publicado: (2020) -
Bazedoxifene Regulates Th17 Immune Response to Ameliorate Experimental Autoimmune myocarditis via Inhibition of STAT3 Activation
por: Wang, Jing, et al.
Publicado: (2021)